Summit Therapeutics Inc.
SMMT
$17.46
-$1.45-7.67%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -67.37% | -164.50% | -310.31% | 91.98% | -90.17% |
| Total Depreciation and Amortization | -26.67% | -37.50% | -56.52% | -70.00% | -94.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.11% | 685.83% | 1,704.68% | -98.28% | -27.02% |
| Change in Net Operating Assets | -108.00% | 114.48% | 122.96% | 2,393.99% | -29.55% |
| Cash from Operations | -150.13% | -103.38% | -12.74% | -129.49% | -474.86% |
| Capital Expenditure | -600.00% | -9.43% | -215.00% | 92.45% | -120.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.85% | -3,062.16% | -20,001,700.00% | 103.08% | -- |
| Cash from Investing | 37.83% | -3,015.75% | -96,756.52% | 103.08% | 605,580.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.08% | -- | -- | -99.54% | 6,506.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -1,306.82% |
| Cash from Financing | -477.67% | 89,044.98% | 250,365.00% | -99.39% | -98.80% |
| Foreign Exchange rate Adjustments | -139.71% | 167.06% | -95.90% | -108.11% | -80.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.72% | 456.60% | -13.88% | 98.30% | -90.96% |
